Learn More at ACEP21 Industry-Supported Satellite Symposia
In-person and webcast opportunities to engage in expanded learning
ACEP21 is your home to a diverse cross-section of emergency medicine education. In addition to its core education program, planned by ACEP’s Educational Meetings Subcommittee, the Scientific Assembly includes an industry-supported satellite symposia.
This year’s satellite symposia features Candid Conversations and Clinical Consults in-person event, “Maintaining Vigilance in the Emergency Department in the Era of Immuno-Oncology: Be Aware, Stay Alert, and Change Your Practice to Ensure Rapid and Accurate Recognition, Triage, Diagnosis, and Treatment of Immune-Related Toxicities.”
Presented live and as a web broadcast, this PeerView Institute for Medical Education-sanctioned event offers expanded discussions of emergency medicine. It is hosted by pharmaceutical companies, AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc., and will provide practical, case-based guidance to ensure accurate recognition, triage, diagnosis, and management of emergency department patients experiencing immune-related adverse events (irAEs) associated with checkpoint inhibitors (ICIs). The event is Monday, October 25, 7-8 a.m. in Grand Ballroom B of the Westin Boston Waterfront.
According to event organizers, patients with a wide variety of malignancies are now experiencing improved treatment outcomes with the rise and expansion of immune ICIs. Through increasing antitumor immunity by blocking intrinsic down regulators of the immune response, ICIs have had a striking impact on the treatment of cancer. With an already comprehensive list of indications as monotherapies and rational combinations, the impact of ICIs is expected to widen, not only in advanced disease but in early-stage, curative-intent settings as well.
Still, ICIs are associated with a spectrum of unique toxicities, or irAEs, which can affect any organ system in the body and occur at any time during or following treatment. Therefore, emergency medicine physicians, advanced practice clinicians, and other healthcare professionals must remain vigilant to mitigate irAEs so that patients can benefit from cancer therapies.
The event will be moderated by Mark M. Awad, MD, PhD and Christopher Baugh, MD, MBA. Learn more at ACEP21 Satellite Symposia.
